Adamis Pharmaceuticals Corporation (ADMP): Price and Financial Metrics


Adamis Pharmaceuticals Corporation (ADMP): $0.24

-0.01 (-5.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ADMP POWR Grades

  • ADMP scores best on the Value dimension, with a Value rank ahead of 67.39% of US stocks.
  • ADMP's strongest trending metric is Quality; it's been moving up over the last 118 days.
  • ADMP's current lowest rank is in the Sentiment metric (where it is better than 10.82% of US stocks).

ADMP Stock Summary

  • With a price/sales ratio of 63.96, ADAMIS PHARMACEUTICALS CORP has a higher such ratio than 96.66% of stocks in our set.
  • With a year-over-year growth in debt of -92.42%, ADAMIS PHARMACEUTICALS CORP's debt growth rate surpasses only 1.79% of about US stocks.
  • As for revenue growth, note that ADMP's revenue has grown -95.19% over the past 12 months; that beats the revenue growth of merely 1.03% of US companies in our set.
  • Stocks that are quantitatively similar to ADMP, based on their financial statements, market capitalization, and price volatility, are GBS, FEMY, TAOP, OCFT, and ALV.
  • ADMP's SEC filings can be seen here. And to visit ADAMIS PHARMACEUTICALS CORP's official web site, go to www.adamispharmaceuticals.com.

ADMP Valuation Summary

  • ADMP's EV/EBIT ratio is -1; this is 109.66% lower than that of the median Healthcare stock.
  • ADMP's price/sales ratio has moved up 34 over the prior 243 months.

Below are key valuation metrics over time for ADMP.

Stock Date P/S P/B P/E EV/EBIT
ADMP 2022-09-09 62.4 7.0 -1.2 -1
ADMP 2022-09-08 61.6 7.0 -1.2 -1
ADMP 2022-09-07 61.3 6.9 -1.2 -1
ADMP 2022-09-06 62.4 7.0 -1.2 -1
ADMP 2022-09-02 61.9 7.0 -1.2 -1
ADMP 2022-09-01 62.8 7.1 -1.3 -1

ADMP Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 93.66%.
  • Its 2 year revenue growth rate is now at -78.21%.
  • The 5 year price growth rate now stands at -80.34%.
ADMP's revenue has moved down $17,635,399 over the prior 21 months.

The table below shows ADMP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.794888 -33.32072 -39.88707
2022-03-31 4.766345 -40.23428 -40.80358
2021-12-31 2.20868 -37.7853 -45.8282
2021-09-30 12.51713 -36.52327 -57.42382
2020-12-31 16.5274 -20.90136 -49.39109
2020-09-30 18.43029 -18.42784 -34.70541

ADMP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADMP has a Quality Grade of F, ranking ahead of 1.65% of graded US stocks.
  • ADMP's asset turnover comes in at 0.414 -- ranking 112th of 682 Pharmaceutical Products stocks.
  • ELTP, XENE, and LPTX are the stocks whose asset turnover ratios are most correlated with ADMP.

The table below shows ADMP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.414 0.099 -4.946
2020-09-30 0.417 0.120 -2.753
2020-06-30 0.432 0.173 -2.533
2020-03-31 0.453 0.289 -2.096
2019-12-31 0.441 0.300 -1.898
2019-09-30 0.393 0.309 -2.593

ADMP Price Target

For more insight on analysts targets of ADMP, see our ADMP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.25 Average Broker Recommendation 2 (Hold)

ADMP Stock Price Chart Interactive Chart >

Price chart for ADMP

ADMP Price/Volume Stats

Current price $0.24 52-week high $1.48
Prev. close $0.25 52-week low $0.18
Day low $0.22 Volume 1,242,400
Day high $0.26 Avg. volume 1,027,756
50-day MA $0.35 Dividend yield N/A
200-day MA $0.49 Market Cap 35.28M

Adamis Pharmaceuticals Corporation (ADMP) Company Bio


Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.


ADMP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMP Latest Social Stream


Loading social stream, please wait...

View Full ADMP Social Stream

Latest ADMP News From Around the Web

Below are the latest news stories about ADAMIS PHARMACEUTICALS CORP that investors may wish to consider to help them evaluate ADMP as an investment opportunity.

Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection. The trial did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. Last year, the company started dosing in the Phase 2/3 trial for Tempol, which was designed to enroll 248 patients. Th

Yahoo | September 21, 2022

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Independent Data Safety Monitoring Board recommends halting the trial SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjec

Yahoo | September 21, 2022

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects. “We are very

Yahoo | September 12, 2022

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled. At the Annual Meeting, all items of business were considered, with the exception of Proposal 2, the proposal to adopt and approve a proposed amendment to the company’s restated certificate of incorporation

Yahoo | August 12, 2022

Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ETSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the second quarter of 2022 and provided an update on recent corporate developm

Yahoo | August 10, 2022

Read More 'ADMP' Stories Here

ADMP Price Returns

1-mo -26.22%
3-mo -46.67%
6-mo -59.75%
1-year -76.92%
3-year -68.27%
5-year -95.43%
YTD -60.33%
2021 24.72%
2020 -30.74%
2019 -68.87%
2018 -48.86%
2017 39.68%

Continue Researching ADMP

Here are a few links from around the web to help you further your research on Adamis Pharmaceuticals Corp's stock as an investment opportunity:

Adamis Pharmaceuticals Corp (ADMP) Stock Price | Nasdaq
Adamis Pharmaceuticals Corp (ADMP) Stock Quote, History and News - Yahoo Finance
Adamis Pharmaceuticals Corp (ADMP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 10.2276 seconds.